Indian businessman to set up pharma plant in Saudi Arabia

Image
Press Trust of India Dubai
Last Updated : Nov 14 2014 | 3:30 PM IST
A UAE-based prominent Indian businessman will invest over USD 266 million to establish a pharmaceutical plant in Saudi Arabia that would manufacture medicine for cancer and dengue.
B R Shetty, managing director and CEO of Neo Pharma, signed an agreement with Prince Turki bin Mohamed bin Nasser, in charge of Jazan Industrial City and Shaikh Mohammed Rafik, chairman of Gammon Group.
Under the agreement, Shetty's company will set up the plant in the Jazan Industrial City, which is being developed by Gammon Group and is expected to attract investments valued at USD 20 billion.
Prince Turki welcomed Shetty and his partners to tap the huge potential of Saudi healthcare market.
"The government's policy is to encourage and support foreign investors to play a great role in developing our economy. The state-owned Saudi Industrial Development Fund will pay the investors 75 per cent of their project cost in interest-free soft loans for 20 years," he said.
Praising Indian expatriates' sincerity to work and honesty in dealings, he underscored the need to further boost the excellent relations with India, Saudi Gazette reported.
"It's an immense pleasure for us to have a leading Indian investor coming to Jazan with big investments. Shetty is enough for us as he can bring his partners to the Kingdom, and this will be good signal for other investors to come and invest," Prince Turki said.
"I have ambitious plans to tap the potential of this holy land, blessed by God, by making investments first in Jazan, then in Jeddah and Riyadh," Shetty said.
"I think it is the right time I entered this great country, which is an ideal destination for investments," he added.
Shetty, whom Forbes Magazine listed in March this year as the fourth richest expatriate billionaire in the UAE, said that the Neo Pharmaceuticals (Neopharma) plant in Jazan would concentrate mainly on manufacturing medicine for cancer and dengue fever.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 14 2014 | 3:30 PM IST

Next Story